Metropolitan Life Insurance Company (MetLife)’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-3,743
| Closed | -$28.9K | – | 1972 |
|
|
2024
Q1 | $28.9K | Sell |
3,743
-697
| -16% | -$5.88K | ﹤0.01% | 1680 |
|
|
2023
Q4 | $39.9K | Hold |
4,440
| – | – | ﹤0.01% | 1565 |
|
|
2023
Q3 | $39.7K | Buy |
4,440
+457
| +11% | +$6.45K | ﹤0.01% | 1532 |
|
|
2023
Q2 | $61.2K | Buy |
3,983
+491
| +14% | +$8.93K | ﹤0.01% | 1309 |
|
|
2023
Q1 | $78.5K | Sell |
3,492
-315
| -8% | -$6.7K | ﹤0.01% | 1131 |
|
|
2022
Q4 | $80.1K | Buy |
3,807
+232
| +6% | +$4.92K | ﹤0.01% | 1186 |
|
|
2022
Q3 | $88.1K | Sell |
3,575
-423
| -11% | -$10.9K | ﹤0.01% | 1088 |
|
|
2022
Q2 | $96.9K | Hold |
3,998
| – | – | ﹤0.01% | 1067 |
|
|
2022
Q1 | $103K | Sell |
3,998
-12,475
| -76% | -$331K | ﹤0.01% | 1173 |
|
|
2021
Q4 | $511K | Hold |
16,473
| – | – | 0.01% | 1406 |
|
|
2021
Q3 | $399K | Hold |
16,473
| – | – | 0.01% | 1598 |
|
|
2021
Q2 | $240K | Buy |
16,473
+826
| +5% | +$16.3K | ﹤0.01% | 2017 |
|
|
2021
Q1 | $391K | Buy |
+15,647
| New | +$432K | 0.01% | 1571 |
|
|
2020
Q4 | – | Sell |
-13,339
| Closed | -$246K | – | 2571 |
|
|
2020
Q3 | $246K | Hold |
13,339
| – | – | ﹤0.01% | 1655 |
|
|
2020
Q2 | $272K | Hold |
13,339
| – | – | ﹤0.01% | 1608 |
|
|
2020
Q1 | $195K | Buy |
13,339
+554
| +4% | +$8.34K | ﹤0.01% | 1604 |
|
|
2019
Q4 | $182K | Sell |
12,785
-1,000
| -7% | -$12.8K | ﹤0.01% | 1988 |
|
|
2019
Q3 | $160K | Hold |
13,785
| – | – | ﹤0.01% | 2033 |
|
|
2019
Q2 | $277K | Hold |
13,785
| – | – | ﹤0.01% | 1674 |
|
|
2019
Q1 | $312K | Hold |
13,785
| – | – | 0.01% | 1603 |
|
|
2018
Q4 | $312K | Hold |
13,785
| – | – | 0.01% | 1529 |
|
|
2018
Q3 | $396K | Hold |
13,785
| – | – | 0.01% | 1529 |
|
|
2018
Q2 | $376K | Buy |
13,785
+627
| +5% | +$16.7K | 0.01% | 1514 |
|
|
2018
Q1 | $294K | Hold |
13,158
| – | – | ﹤0.01% | 1630 |
|
|
2017
Q4 | $277K | Sell |
13,158
-11,607
| -47% | -$265K | ﹤0.01% | 1683 |
|
|
2017
Q3 | $616K | Sell |
24,765
-626
| -2% | -$13.8K | ﹤0.01% | 1546 |
|
|
2017
Q2 | $492K | Buy |
25,391
+888
| +4% | +$16.1K | ﹤0.01% | 1703 |
|
|
2017
Q1 | $452K | Sell |
24,503
-718
| -3% | -$14K | ﹤0.01% | 1717 |
|
|
2016
Q4 | $477K | Hold |
25,221
| – | – | ﹤0.01% | 1767 |
|
|
2016
Q3 | $564K | Buy |
25,221
+592
| +2% | +$11.3K | ﹤0.01% | 1630 |
|
|
2016
Q2 | $439K | Hold |
24,629
| – | – | ﹤0.01% | 1782 |
|
|
2016
Q1 | $336K | Hold |
24,629
| – | – | ﹤0.01% | 1826 |
|
|
2015
Q4 | $475K | Hold |
24,629
| – | – | ﹤0.01% | 1654 |
|
|
2015
Q3 | $499K | Hold |
24,629
| – | – | ﹤0.01% | 1634 |
|
|
2015
Q2 | $816K | Buy |
+24,629
| New | +$675K | 0.01% | 1426 |
|
|
2015
Q1 | – | Sell |
-20,202
| Closed | -$247K | – | 2435 |
|
|
2014
Q4 | $247K | Hold |
20,202
| – | – | ﹤0.01% | 2256 |
|
|
2014
Q3 | $182K | Hold |
20,202
| – | – | ﹤0.01% | 2456 |
|
|
2014
Q2 | $237K | Hold |
20,202
| – | – | ﹤0.01% | 2387 |
|
|
2014
Q1 | $430K | Buy |
+20,202
| New | +$311K | ﹤0.01% | 1916 |
|
Other funds holding TVTX
AC
DTC
RSCM
Metropolitan Life Insurance Company (MetLife)'s TVTX Position: Q2 2024 in Review
Metropolitan Life Insurance Company (MetLife) sold out of Travere Therapeutics (TVTX) in Q2 2024, closing a stake of 3,743 shares — an estimated $28.9K sold.
Metropolitan Life Insurance Company (MetLife) first reported a position in TVTX in Q1 2014 and held it in 39 quarters. The position peaked at $816K in Q2 2015. 173 funds tracked by Wall St. Rank hold TVTX as of Q2 2024.
- Metropolitan Life Insurance Company (MetLife) reported no remaining Travere Therapeutics position as of Q2 2024 after selling out during the quarter.
- Metropolitan Life Insurance Company (MetLife) sold 3,743 Travere Therapeutics shares in Q2 2024, an estimated $28.9K.
- Metropolitan Life Insurance Company (MetLife) first reported a position in Travere Therapeutics in Q1 2014 and held it in 39 quarters.
- Metropolitan Life Insurance Company (MetLife)'s Travere Therapeutics position peaked at $816K in Q2 2015.
- 173 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2024.
Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.